期刊文献+

探讨新型口服抗凝药物在高龄老年房颤人群中的应用

下载PDF
导出
摘要 目的:探讨新型口服抗凝药物在高龄老年房颤人群中的应用效果。方法:选取62例2015年元月至2016年年末于本院接受口服抗凝药物常规和新型口服抗凝药物治疗的高龄老年房颤患者的医疗病例档案资料,按药物应用类型分为常规组30例和新型组32例,对其进行回顾性统计学对比分析,以探讨新型口服抗凝药物在高龄老年房颤人群中的应用效果。结果:32例新型组高龄老年房颤患者的总疗效率为96.88%(31/32),其中应用显效25例、应用有效6例、应用无效1例;30例常规组高龄老年房颤患者的总疗效率为83.33%(25/30),其中应用显效16例、应用有效9例、应用无效5例。两组应用效果差异的统计学对比意义显著(P<0.05)。结论:新型口服抗凝药物在高龄老年房颤人群中的应用效果显著,其可有效控制房颤的发生及进展,可获得较常规口服抗凝药物更为理想的预后,对高龄老年房颤人群的生存质量的可起到更好的保障作用。
作者 李拥军
出处 《中国农村卫生》 2017年第14期45-45,共1页
  • 相关文献

参考文献6

二级参考文献74

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1398
  • 2January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm So- ciety[J]. Circulation.2014.130(23):2071-2104.
  • 3Weitz JI, Eikelboom JW, Samama MM. New antithrom- botic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physi- cians Evidence-Based Clinical Practice Guidelines [J]. Chest,2012,141(2 Suppl):el20S-el51S.
  • 4Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for heahhcare professionals from the American Heart Asso- ciation/American Stroke Association[J]. Stroke,2014,45(5): 1545-1588.
  • 5Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of a- trial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J,2012,33(21):2719-2747.
  • 6Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabi- gatran versus warfarin in patients with mechanical heart valves[J]. N Engl J Med,2013,369(13):1206-1214.
  • 7Van de Wed F, Brueckmann M, Connolly S J, et al. A comparison of dabigatran etexilate with warfarin in pa- tients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacoki- netics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)[J]. Am Heart J,2012,163 (6):931-937.
  • 8Nieuwlaat R, Capucci A, Carom AJ, et al. Atrial fibrilla- tion management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation[J]. Eur Heart J,2005,26(22):2422-2434.
  • 9Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrilla- tion: primary results of the prevention of thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)[J]. Europaee,2014,16(1):6-14.
  • 10Breithardt G, Baumgartner H, Berkowitz SD, et al. Clini- cal characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease par- ticipating in the ROCKET AF trial[J]. Eur Heart J, 2014,35(47):3377-3385.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部